Comparison between Evoq Remedies IPO and P.E.Analytics IPO.
IPO Details
Evoq Remedies IPO is a SME Bookbuilding IPO proposed to list at BSE SME while P.E.Analytics IPO is a SME Bookbuilding proposed to list at NSE SME.
Issue Size and Price
The total issue size of Evoq Remedies IPO is up to ₹9.23 Cr whereas the issue size of the P.E.Analytics IPO is up to ₹30.01 Cr. The final issue price of Evoq Remedies IPO is ₹27.00 per share and of P.E.Analytics IPO is ₹114.00 per share.
| | Evoq Remedies IPO | P.E.Analytics IPO |
|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | | ₹111.00 per share |
| Issue Price (Upper) | | ₹114.00 per share |
| Issue Price (Final) | ₹27.00 per share | ₹114.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Market Lot Size | 4000 shares | 1200 shares |
| Fresh Issue Size | 34,20,000 shares | 13,12,800 shares |
| Fresh Issue Size (Amount) | up to ₹9.23 Cr | up to ₹14.97 Cr |
| OFS Issue Size | 0 shares | 13,20,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹15.05 Cr |
| Issue Size Total | 34,20,000 shares | 26,32,800 shares |
| Issue Size Total (Amount) | up to ₹9.23 Cr | up to ₹30.01 Cr |
IPO Timetable
Evoq Remedies IPO opens on Mar 17, 2022, while P.E.Analytics IPO opens on Mar 22, 2022. The closing date of Evoq Remedies IPO and P.E.Analytics IPO is Mar 22, 2022, and Mar 25, 2022, respectively.
| | Evoq Remedies IPO | P.E.Analytics IPO |
|---|
| Anchor Bid Date | | Mar 21, 2022 |
| Issue Open | Mar 17, 2022 | Mar 22, 2022 |
| Issue Close | Mar 22, 2022 | Mar 25, 2022 |
| Basis Of Allotment (Tentative) | Mar 25, 2022 | Mar 30, 2022 |
| Initiation of Refunds (Tentative) | Mar 28, 2022 | Mar 31, 2022 |
| Credit of Share (Tentative) | Mar 29, 2022 | Apr 01, 2022 |
| Listing date (Tentative) | Mar 30, 2022 | Apr 04, 2022 |
| Anchor Lockin End date 1 | | Apr 29, 2022 |
Financials & KPIs
Evoq Remedies IPO P/E ratio is 33.75, as compared to P.E.Analytics IPO P/E ratio of 14.56.
Shares Offered
In the Evoq Remedies IPO Retail Individual Investors (RII) are offered 17,10,000 shares while in P.E.Analytics IPO retail investors are offered 17,10,000 shares. Qualified Institutional Buyers (QIB) are offered in Evoq Remedies IPO and 5,26,800 shares in P.E.Analytics IPO.
| | Evoq Remedies IPO | P.E.Analytics IPO |
|---|
| Anchor Investor Reservation | | 7,88,400 shares |
| Market Maker Reservation | 1,80,000 shares | 1,39,200 shares |
| QIB | | 5,26,800 shares |
| NII | 17,10,000 shares | 3,96,000 shares |
| RII | 17,10,000 shares | 9,21,600 shares |
| Employee | | 0 shares |
| Total | 34,20,000 shares | 26,32,800 shares |
Bids Received (Subscription)
Evoq Remedies IPO subscribed 1.67x in total, whereas P.E.Analytics IPO subscribed 46.34x.
